NICE has recommended in draft guidance that UCB’s Cimzia can receive regular NHS funding ... red scaly plaques on the skin. A digital health passport is an app, or online certification, that ...

The US FDA has approved a label extension for UCB’s Cimzia (certolizumab pegol ... chronic inflammatory disease primarily affecting the skin. Signs and symptoms vary but may include red ...

In April 2008, certolizumab pegol (Cimzia; UCB), a tumour-necrosis factor blocker, was approved by the US FDA for the treatment of adult patients with moderate-to-severe Crohn's disease who have ...